A Reexamination of the PPAR-α Activation Mode of Action as a Basis for Assessing Human Cancer Risks of Environmental Contaminants
- 1 November 2009
- journal article
- review article
- Published by Environmental Health Perspectives in Environmental Health Perspectives
- Vol. 117 (11), 1664-1672
- https://doi.org/10.1289/ehp.0900758
Abstract
A peer-reviewed open access journal published by the National Institute of Environmental Health SciencesKeywords
This publication has 110 references indexed in Scilit:
- Epigenetic effects of the continuous exposure to peroxisome proliferator WY-14,643 in mouse liver are dependent upon peroxisome proliferator activated receptor αMutation Research, 2007
- Difficulty of mode of action determination for trichloroethylene: An example of complex interactions of metabolites and other chemical exposuresEnvironmental and Molecular Mutagenesis, 2007
- The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARαToxicological Sciences, 2007
- Present concepts and future outlook: Function of peroxisome proliferator‐activated receptors (PPARs) for pathogenesis, progression, and therapy of cancerJournal of Cellular Physiology, 2007
- Hepatocyte-restricted constitutive activation of PPAR induces hepatoproliferation but not hepatocarcinogenesisCarcinogenesis: Integrative Cancer Research, 2007
- Modes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the LiverCritical Reviews in Toxicology, 2006
- Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeysCarcinogenesis: Integrative Cancer Research, 2004
- The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐upJournal of Internal Medicine, 1994
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Gallbladder Disease as a Side Effect of Drugs Influencing Lipid Metabolism Experience in the Coronary Drug ProjectNew England Journal of Medicine, 1977